Lubner David Charles

SEC source: 0001470831-26-000796 · wk-form4_1786134631.xml · nonDerivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,555

SEC source: 0001470831-26-000796 · wk-form4_1786134631.xml · derivative · entry 2

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2036-08-04

F1 · derivative.exercise_date: 1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001193125-26-264025 · ownership.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,152

Underlying: Common Stock · 35,152 shares

Expires 2036-06-04

F1 · derivative.exercise_date: This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

SEC source: 0001628280-26-040582 · wk-form4_1780530489.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,050

Underlying: Ordinary Shares · 11,050 shares

Expires 2036-06-02

F1 · derivative.exercise_date: This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001572000-26-000002 · form4-04282026_080414.xml · derivative · entry 8

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,174 shares

Expires 2035-05-29

F2 · price: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.

SEC source: 0001572000-26-000002 · form4-04282026_080414.xml · derivative · entry 7

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,011 shares

Expires 2034-05-28

F2 · price: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.

SEC source: 0001572000-26-000002 · form4-04282026_080414.xml · derivative · entry 6

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,459 shares

Expires 2033-06-14

F2 · price: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.

SEC source: 0001572000-26-000002 · form4-04282026_080414.xml · derivative · entry 5

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 61,538 shares

Expires 2032-02-03

F2 · price: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.

SEC source: 0001572000-26-000002 · form4-04282026_080414.xml · derivative · entry 4

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 31,794 shares

Expires 2031-12-07

F2 · price: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.

SEC source: 0001572000-26-000002 · form4-04282026_080414.xml · derivative · entry 3

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 59,405 shares

Expires 2031-06-09

F2 · price: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.

SEC source: 0001572000-26-000002 · form4-04282026_080414.xml · derivative · entry 2

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,626 shares

Expires 2030-08-31

F2 · price: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.

SEC source: 0001572000-26-000002 · form4-04282026_080414.xml · nonDerivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share ("Closing Amount"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.

SEC source: 0001193125-26-187601 · ownership.xml · nonDerivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001193125-26-017002 · ownership.xml · derivative · entry 3

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,405

Underlying: Common Stock · 6,000 shares

Expires 2031-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2017 Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean June 9, 2021.

SEC source: 0001193125-26-017002 · ownership.xml · nonDerivative · entry 2

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,659

F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 29, 2025.

SEC source: 0001193125-26-017002 · ownership.xml · nonDerivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,659

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001610717-25-000303 · form4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2035-06-17

F1 · price: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2]

F2 · price: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]

F3 · price: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration.

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2]

F2 · derivative.exercise_date: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]

F3 · derivative.exercise_date: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration.

SEC source: 0001104659-25-061816 · tm2518376-13_4seq1.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,023

Underlying: Ordinary Shares · 9,023 shares

Expires 2035-06-23

F1 · derivative.exercise_date: This option represents a right to purchase shares of the Issuer's ordinary shares and vests in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001610717-25-000245 · form4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-06-17

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) the one year anniversary of June 18, 2025 or (ii) the next Annual Meeting following June 18, 2025, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0000950170-25-081358 · ownership.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2035-05-29

F1 · derivative.exercise_date: This option was granted on May 30, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 30, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.

SEC source: 0001415889-25-014980 · form4-05302025_080509.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,174

Underlying: Common Stock · 9,174 shares

Expires 2035-05-29

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of May 29, 2026 or the next annual meeting of stockholders.

SEC source: 0001415889-25-014529 · form4-05232025_050508.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-05-21

F1 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 22, 2026 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001610717-24-000300 · form4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,742

Underlying: Common Stock · 23,742 shares

Expires 2034-06-03

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 4, 2024 (the "Vesting Commencement Date") or (ii) the next Annual Meeting following June 4, 2024, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001415889-24-015741 · form4-06062024_080643.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,011

Underlying: Common Stock · 8,011 shares

Expires 2034-05-28

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of May 28, 2025 or the next annual meeting of stockholders.

SEC source: 0001415889-24-014648 · form4-05282024_040514.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-05-22

F1 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 23, 2025 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0000950170-24-064724 · ownership.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,133

Underlying: Common Stock · 25,133 shares

Expires 2034-05-21

F1 · derivative.exercise_date: This option was granted on May 22, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 22, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to continued service.

SEC source: 0001104659-23-129769 · tm2333785-3_4seq1.xml · derivative · entry 5

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 44,749 shares

Expires 2029-06-01

F2 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

SEC source: 0001104659-23-129769 · tm2333785-3_4seq1.xml · derivative · entry 4

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,614 shares

Expires 2028-06-02

F2 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

SEC source: 0001104659-23-129769 · tm2333785-3_4seq1.xml · derivative · entry 3

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2027-07-06

F2 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

SEC source: 0001104659-23-129769 · tm2333785-3_4seq1.xml · nonDerivative · entry 2

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.

SEC source: 0001104659-23-129769 · tm2333785-3_4seq1.xml · nonDerivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,600

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.

SEC source: 0001610717-23-000348 · form4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2033-11-08

F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from November 10, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.

SEC source: 0001209191-23-037830 · doc4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,459

Underlying: Common Stock · 11,459 shares

Expires 2033-06-14

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 14, 2024 or the next annual meeting of stockholders.

SEC source: 0001104659-23-068141 · tm2317857-1_4seq1.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,749

Underlying: Common Stock · 44,749 shares

Expires 2029-06-01

F1 · derivative.exercise_date: The option will vest 100% on the first anniversary of the grant date.

SEC source: 0001209191-23-033810 · doc4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-05-25

F1 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 26, 2024 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-23-032278 · doc4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,900

Underlying: Common Stock · 24,900 shares

Expires 2033-05-23

F1 · derivative.exercise_date: This option was granted on May 24, 2023. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 24, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders.

SEC source: 0001104659-22-122395 · tm2231459-2_4seq1.xml · nonDerivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,600

SEC source: 0001209191-22-041337 · doc4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,222

Underlying: Common Stock · 7,222 shares

Expires 2030-07-30

F1 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

SEC source: 0001209191-22-037501 · doc4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,911

Underlying: Common Stock · 16,911 shares

Expires 2032-06-13

F1 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-22-034495 · doc4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,596

Underlying: Common Stock · 19,596 shares

Expires 2032-06-02

F1 · derivative.exercise_date: This option was granted on June 3, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders.

SEC source: 0001104659-22-068509 · tm2217697-3_4seq1.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,614

Underlying: Common Stock · 25,614 shares

Expires 2028-06-02

F1 · derivative.exercise_date: The option will vest 100% on the first anniversary of the grant date.

SEC source: 0001209191-22-008159 · doc4.xml · derivative · entry 2

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,659 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series C Preferred Stock into Common Stock had no expiration date.

F1 · price: Each share of Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series C Preferred Stock into Common Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series C Preferred Stock into Common Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series C Preferred Stock into Common Stock had no expiration date.

SEC source: 0001209191-22-008159 · doc4.xml · nonDerivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,659

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series C Preferred Stock into Common Stock had no expiration date.

SEC source: 0001209191-22-007567 · doc4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,538

Underlying: Common Stock · 61,538 shares

Expires 2032-02-03

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option will vest each year following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "Equity Grant Date" shall mean February 3, 2022.

SEC source: 0000899243-21-039453 · doc4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,245

Underlying: Common Stock · 17,245 shares

Expires 2031-10-03

F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date.

SEC source: 0001209191-22-017668 · doc4a.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires not disclosed

F1 · derivative.exercise_price: This Form 4/A amends and restates the original Form 4 filed on October 6, 2021 ("Original Form 4"). The stock option reported on the Original Form 4 was reported in error and was never granted to the Reporting Person.

F1 · derivative.exercise_date: This Form 4/A amends and restates the original Form 4 filed on October 6, 2021 ("Original Form 4"). The stock option reported on the Original Form 4 was reported in error and was never granted to the Reporting Person.

F1 · derivative.expiration_date: This Form 4/A amends and restates the original Form 4 filed on October 6, 2021 ("Original Form 4"). The stock option reported on the Original Form 4 was reported in error and was never granted to the Reporting Person.

SEC source: 0001104659-21-090262 · tm2121760-8_4seq1.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2027-07-06

F1 · derivative.exercise_date: The option vests 25% on July 6, 2022 with the remaining 75% vesting in three equal annual installments thereafter.

SEC source: 0000899243-21-020985 · doc4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,596

Underlying: Common Stock · 19,596 shares

Expires 2031-05-25

F1 · derivative.exercise_date: This option was granted on May 26, 2021. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 26, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders

SEC source: 0001213900-21-015393 · ownership.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-03-11

F1 · derivative.exercise_date: This option shall vest and become exercisable in 36 equal monthly installments following the Grant Date, provided that as of each such date the Grantee remains in a business relationship with the Company.

SEC source: 0001209191-22-017671 · doc4a.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,529

Underlying: Common Stock · 17,529 shares

Expires 2031-03-11

F1 · derivative.exercise_date: This option shall vest and become exercisable in 36 equal monthly installments following the Grant Date, provided that as of each such date the Grantee remains in a business relationship with the Company.